Cilansetron

Cilansetron

Clinical data
Pregnancy category	C
Routes of administration	Oral
ATC code	A03AE03 (WHO)
Legal status
Legal status	Unlicensed
Pharmacokinetic data
Bioavailability	87%
Metabolism	Hepatic
Elimination half-life	1.6 - 1.9 hours
Excretion	Renal
Identifiers
IUPAC name (10R)-10-[(2-methyl-1H-imidazol-1-yl)methyl]-5,6,9,10 -tetrahydro-4H-pyrido(3,2,1-jk)carbazol-11-one
CAS Number	120635-74-7 Y
PubChem CID	6918107
ChemSpider	5293321 Y
UNII	2J6DQ1U5B5
KEGG	D03495 Y
ChEMBL	ChEMBL2103778
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H21N3O
Molar mass	319.4 g/mol
3D model (JSmol)	Interactive image
SMILES O=C3c2c1cccc5c1n(c2CC[C@@H]3Cn4ccnc4C)CCC5
InChI InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1 Y Key:NCNFDKWULDWJDS-OAHLLOKOSA-N Y
(verify)

WikiDoc Resources for Cilansetron
Articles
Most recent articles on Cilansetron Most cited articles on Cilansetron Review articles on Cilansetron Articles on Cilansetron in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cilansetron Images of Cilansetron Photos of Cilansetron Podcasts & MP3s on Cilansetron Videos on Cilansetron
Evidence Based Medicine
Cochrane Collaboration on Cilansetron Bandolier on Cilansetron TRIP on Cilansetron
Clinical Trials
Ongoing Trials on Cilansetron at Clinical Trials.gov Trial results on Cilansetron Clinical Trials on Cilansetron at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cilansetron NICE Guidance on Cilansetron NHS PRODIGY Guidance FDA on Cilansetron CDC on Cilansetron
Books
Books on Cilansetron
News
Cilansetron in the news Be alerted to news on Cilansetron News trends on Cilansetron
Commentary
Blogs on Cilansetron
Definitions
Definitions of Cilansetron
Patient Resources / Community
Patient resources on Cilansetron Discussion groups on Cilansetron Patient Handouts on Cilansetron Directions to Hospitals Treating Cilansetron Risk calculators and risk factors for Cilansetron
Healthcare Provider Resources
Symptoms of Cilansetron Causes & Risk Factors for Cilansetron Diagnostic studies for Cilansetron Treatment of Cilansetron
Continuing Medical Education (CME)
CME Programs on Cilansetron
International
Cilansetron en Espanol Cilansetron en Francais
Business
Cilansetron in the Marketplace Patents on Cilansetron
Experimental / Informatics
List of terms related to Cilansetron

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cilansetron is a drug that is a 5HT-3 antagonist currently under trial phase in the EU and US it is manufactured by Solvay Pharmaceuticals INC.

5HT-3 receptors are responsible for causing many things from nausea to excess bowel movements. It is thought in conditions like irritable bowel syndrome (IBS) the receptors have become faulty or oversensitive. 5HT-3 antagonists work by blocking the nervous and chemical signals from reaching these receptors.

Studies have shown that the drug can greatly improve quality of life in men and women with diahorrea predominant IBS (1) Cilansetron is the first 5HT antagonist specifically designed for IBS that is effective in men as well as women.(1)

Solvay has had considerable difficulty with the medicines regulators in the UK, EU and USA with regards to licensing the drug. This could possibly be due to the problems discovered after licensing with the drug Lotronex. At time of writing; Solvay had recently withdrawn its application to the U.S. Food and Drug Administration (FDA) but was continuing its talks with the MHRA in the UK and EU regulators. (2)

It is not currently known what sort of timeframe the public are looking at to be able to obtain the drug. This matter is not helped by the lack of information about cilansetron and its trials in the public domain. The regulators have also stated this in their responses.

There is no information about future trials currently available.

Some people have tried the Anti-emetic ondansetron HCl (Zofran) as a substitute for the time being, results are mixed but noted effect has been shown in some males and females (3) However; due to its license in the UK it is usually only prescribable at consultant level. Since the licensing of a generic version it is more likely an NHS prescription will be accepted as the branded version is very expensive (Official NHS pricing.) In the USA and Canada: availability often depends on insurance and the doctors personal opinion on off-label prescribing.

References

1. http://www.drugdevelopment-technology.com/projects/cilanserton (General info on Cilansetron.)
2. http://www.solvaypress.com/pressreleases/0,,36423-2-0,00.htm#contact (Sovay press relaase 19 November 2005.)
3. http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2036.1996.30172000.x (Clinical trial for 5-HT3 antagonists use in Diarrhoea-predominant IBS)